J Pharmacol Exp Ther 2018 03 8;364(3):474-484. Epub 2018 Jan 8.
AbbVie Bioresearch Center, Worcester, Massachusetts (M.C.R., L.H., T.T.Z., S.B., P.F.S., C.A.C., C.T.); and AbbVie Deutschland, Ludwigshafen, Germany (G.B.).
Despite the efficacy of biologics for treatment of rheumatoid arthritis (RA), many patients show inadequate responses and likely require neutralization of multiple mediators. Neutralization of both interleukin (IL)-1 and IL-17A with monoclonal antibodies showed greater efficacy than either agent alone in a mouse arthritis model with cooperative inhibition of key inflammatory factors, IL-6, granulocyte colony-stimulating factor (G-CSF), and CXC chemokine ligand (CXCL)1. Given the potential clinical benefit in RA, we generated a human dual variable domain antibody Ig, ABBV-615, capable of simultaneous binding and neutralization of IL-1 and IL-17A. Read More